X
Xinan Wang
Researcher at Harvard University
Publications - 25
Citations - 243
Xinan Wang is an academic researcher from Harvard University. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 4 publications receiving 19 citations.
Papers
More filters
Journal ArticleDOI
Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
Biagio Ricciuti,Kathryn C. Arbour,Jessica J. Lin,Amir Vajdi,Natalie I. Vokes,Lingzhi Hong,Jianjun Zhang,Michael Y. Tolstorukov,Yvonne Y. Li,Yvonne Y. Li,Liam F. Spurr,Liam F. Spurr,Andrew D. Cherniack,Andrew D. Cherniack,Gonzalo Recondo,Giuseppe Lamberti,Xinan Wang,Deepti Venkatraman,Joao Victor Machado Alessi,Victor Vaz,Hira Rizvi,Jacklynn V. Egger,Andrew J. Plodkowski,Sara Khosrowjerdi,Subba R. Digumarthy,Hye Sun Park,Nuno Vaz,Mizuki Nishino,Lynette M. Sholl,David A. Barbie,Mehmet Altan,John V. Heymach,Ferdinandos Skoulidis,Justin F. Gainor,Matthew D. Hellmann,Mark M. Awad +35 more
TL;DR: In this paper, clinical outcomes to PD-(L)1 inhibition were analyzed according to KRAS, STK11, and KEAP1 mutation status in two independent and combined cohorts.
Journal ArticleDOI
Association of High Tumor Mutation Burden in Non–Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels
Biagio Ricciuti,Xinan Wang,Joao Victor Machado Alessi,Hira Rizvi,Navin R. Mahadevan,Yvonne Y. Li,Andrew Polio,James Lindsay,Renato Umeton,Rileen Sinha,Natalie I. Vokes,Gonzalo Recondo,Giuseppe Lamberti,Marissa N. Lawrence,V. Vaz,Giulia Costanza Leonardi,Andrew J. Plodkowski,Hersh Gupta,Andrew D. Cherniack,Michael Y. Tolstorukov,Bijaya Sharma,Kristen Felt,Justin F. Gainor,Arvind Ravi,Gad Getz,Kurt A. Schalper,Brian Henick,Patrick M. Forde,Valsamo Anagnostou,Pasi A. Jänne,Eliezer M. Van Allen,Mizuki Nishino,Lynette M. Sholl,David C. Christiani,Xihong Lin,Scott J. Rodig,Matthew D. Hellmann,Mark M. Awad +37 more
TL;DR: It is suggested that in NSCLC, a high number of nonsynonymous tumor mutations is associated with immune cell infiltration and inflammatory T-cell expression signatures, leading to increased sensitivity to PD-1/PD-L1 inhibition across PD-L 1 expression subgroups.
Journal ArticleDOI
Association between Smoking History and Tumor Mutation Burden in Advanced Non-Small Cell Lung Cancer.
Xinan Wang,Biagio Ricciuti,Tom C. Nguyen,Xihao Li,Michael S. Rabin,Mark M. Awad,Xihong Lin,Bruce E. Johnson,David C. Christiani +8 more
TL;DR: In this paper, the authors investigated the relationship between smoking history and clinically relevant mutations in non-small cell lung cancer, revealing the potential of smoking history as a surrogate for tumor mutation burden.
Journal ArticleDOI
Smoking History as a Potential Predictor of Immune Checkpoint Inhibitor Efficacy in Metastatic Non-Small Cell Lung Cancer.
Xinan Wang,Biagio Ricciuti,Joao Victor Machado Alessi,Tom C. Nguyen,Mark M. Awad,Xihong Lin,Bruce E. Johnson,David C. Christiani +7 more
TL;DR: In this article, a study was conducted on 644 advanced non-small cell lung cancer (NSCLC) patients treated with ICI monotherapy between April 2013 and September 2020 at the Dana-Farber Cancer Institute and Brigham and Women's Hospital.
Journal ArticleDOI
Comparative analysis and isoform-specific therapeutic vulnerabilities of KRAS mutations in non-small cell lung cancer.
Biagio Ricciuti,Jieun Son,Jeffrey J. Okoro,Alessia Mira,Enrico Patrucco,Yoonji Eum,Xinan Wang,Raymond M. Paranal,Haiyun Wang,Mika Lin,Heidi M. Haikala,Jiaqi Li,Yue Xu,Joao Victor Machado Alessi,Chhayheng Chhoeu,Amanda J. Redig,Jens Köhler,Kshiti Dholakia,Yunhan Chen,Elodie Richard,Marie-Julie Nokin,David Santamaría,Prafulla C. Gokhale,Mark M. Awad,Pasi A. Jänne,Chiara Ambrogio +25 more
TL;DR: This study demonstrates that KRAS isoforms are highly heterogeneous in terms of concurrent genomic alterations and gene expression profiles, and that stratification based on KRAS alleles should be considered in the design of future clinical trials.